Medical oncologists and breast cancer specialists treating adults with ER-positive, HER2-negative advanced or metastatic breast cancer now have an FDA‑approved oral heterobifunctional protein degrader, vepdegestrant, specifically for tumors with ESR1 mutations detected by an FDA‑authorized test [2]. The approval is supported by VERITAC-2 efficacy in the ESR1-mutant subgroup showing improved median PFS and higher ORR versus fulvestrant, and the labeling includes a companion diagnostic for patient selection [2]. How clinicians will integrate vepdegestrant with existing endocrine agents and how pending regulatory decisions on camizestrant will affect sequencing remain open questions?
Dr. Meera Pillai, MBBS, MD (General Medicine), DM (Medical Oncology) · Oncology
The FDA approved vepdegestrant (Veppanu) on May 1, 2026, for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1‑mutated advanced or metastatic breast cancer after progression on at least one line of endocrine therapy, based on VERITAC-2 showing a progression‑free survival benefit (median PFS 5 months vs 2.1 months; HR 0.57; 95% CI: 0.42-0.77) [2]. The approval included the Guardant360 CDx as a companion diagnostic and a recommended oral dose of 200 mg once daily with food (consult current prescribing information for full dosing guidance) [2].
Clinical Context
Vepdegestrant is described in the FDA review as a heterobifunctional protein degrader developed by Arvinas Operations, Inc. and was evaluated in VERITAC-2, a randomized, open-label, active-controlled trial in advanced ER-positive, HER2-negative breast cancer with ESR1 mutations [2]. Fulvestrant, an injectable estrogen receptor antagonist and ER downregulator, remains an available endocrine option with labeled indications for HR-positive, HER2-negative advanced or metastatic breast cancer and defined intramuscular dosing (500 mg loading schedule) [1][5] (consult current prescribing information for full dosing guidance). Camizestrant (AstraZeneca; NDA# 220359) was the subject of an FDA Oncologic Drugs Advisory Committee meeting on April 30, 2026, with the SERENA-6 study cited in briefing materials, but efficacy details were not available in the provided excerpts [3][4]. Elacestrant was not reported in the provided source excerpts.
- What is vepdegestrant (Veppanu) approved for?
Vepdegestrant (Veppanu) is approved for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1‑mutated advanced or metastatic breast cancer, as detected by an FDA‑authorized test, with disease progression following at least one line of endocrine therapy; the approval included the Guardant360 CDx as a companion diagnostic to identify ESR1 mutations for treatment selection.
- How does vepdegestrant work?
Vepdegestrant is described in the FDA review as a heterobifunctional protein degrader. The application and approval materials characterize vepdegestrant as a degrader of the estrogen receptor pathway, evaluated for clinical efficacy in patients whose tumors harbor ESR1 mutations. Additional mechanistic details beyond this classification were not available in the provided source excerpts.
- What is the recommended dose of vepdegestrant?
The recommended vepdegestrant dose in the FDA approval is 200 mg taken orally once daily with food and continued until disease progression or unacceptable toxicity (consult current prescribing information for full dosing guidance).
- What are the most important safety considerations for vepdegestrant?
The prescribing information for vepdegestrant includes warnings and precautions for QTc interval prolongation and embryo-fetal toxicity; these labeled risks were noted in the FDA approval materials. Specific adverse event rates beyond these labeled warnings were not reported in the provided source excerpts, and prescribers should consult the full prescribing information for comprehensive safety data.